Why is Integra LifeSciences stock tumbling today?
Integra LifeSciences (IART) shares fell 16.2% to $13.49 after lowering its 2026 revenue and EPS guidance due to flooding damage at a key facility. The company expects $7M in Q3 revenue loss and $15M-$20M in Q4. It also announced a $600M debt refinancing. The stock dropped despite a positive U.S. market day.
How this was made
The 30-second read
Why it matters
The combined guidance cut and debt raise created a sharp sell‑off, despite a broadly positive market backdrop.
Market read
Integra's stock fell 16.2% on guidance miss, contrasting with a rising S&P 500, highlighting a company‑specific risk.
What to watch
Potential upside from the $600 M senior secured loan could improve liquidity if market perceives it as a strategic refinancing.
Background
Integra LifeSciences announced a flood‑related production hit at its Cincinnati facility and simultaneously launched a $600 M senior secured term loan.
Ticker impact
Integra LifeSciences released preliminary Q3 results and cut full‑year 2026 revenue and EPS guidance, triggering a 16.2% drop in its stock.
likely continued downward pressure as investors price in lower revenue and earnings forecasts
The guidance cut is material, the flood impact reduces capacity through Q4 2026, and the debt refinancing adds leverage concerns, all of which support further sell‑off.
Market effects
Medical‑technology sector may see broader risk‑off as supply‑chain disruptions raise concerns.
U.S. equities largely up, but Integra's drop stands out as a company‑specific outlier.
Limited; impact confined to Integra and its niche market.
Counterpoint
If insurance recoveries exceed expectations, the downside could be overstated.
Key entities
- ExecutiveStuart Essig
CEO of Integra LifeSciences, cited flood impact on results.
- ExecutiveLea Knight
CFO, described the purpose of the new senior secured loan.
